17 citations
,
April 2023 in “Cell Biology International” RDW is a useful, cost-effective tool for diagnosing and monitoring various diseases.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
2 citations
,
November 2025 in “Pharmaceutics” Cell-mediated drug delivery systems improve skin disease treatment by using living cells for precise, prolonged, and less toxic therapy.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
16 citations
,
December 2021 in “Journal of Integrative Neuroscience” miR-325-3p can slow down brain tumor growth by targeting FOXM1.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
February 2023 in “Scientific Reports” Cold Atmospheric Microwave Plasma (CAMP) helps hair cells grow and could potentially treat hair loss.
June 2025 in “British Journal of Dermatology” The new AI software predicts melanoma outcomes more accurately than traditional methods.
6 citations
,
July 2009 in “Veterinary dermatology” Vesiculobullous lesions should be considered part of canine cutaneous epitheliotropic T-cell lymphoma.
822 citations
,
January 2021 in “Genome biology” scMC effectively separates biological signals from technical noise in single-cell genomics data.
38 citations
,
September 2004 in “Journal of Autoimmunity” Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
26 citations
,
May 2020 in “JCI Insight” Alopecia areata involves specific immune cells, offering potential treatment targets.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
12 citations
,
February 2018 in “Scientific Reports” Using a drug to activate bone marrow stem cells can help the liver regenerate and function better after major surgery in rats.
12 citations
,
January 1991 in “Acta Dermato Venereologica” Basal cell epithelioma-like changes are most similar to normal basal cells.
11 citations
,
January 1999 in “Dermatology”
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
August 2018 in “Dermatologic Surgery”
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
39 citations
,
October 2012 in “Familial cancer” New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.
OCT4B1 and SOX-2 levels are higher in Crohn's and ulcerative colitis patients, possibly aiding tissue repair.
31 citations
,
October 1992 in “PubMed” A mycobacterial protein shares a similar region with a human skin protein, possibly affecting skin diseases.
3 citations
,
November 2013 in “Journal of Stem Cells and Regenerative Medicine” Imaging intestinal stem cells might help detect early signs of colorectal cancer.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
5 citations
,
June 1994 in “Journal of Cutaneous Pathology” No CD44 in alopecia areata, present in normal and androgenetic alopecia.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
2 citations
,
April 2023 in “American Journal of Dermatopathology” CCCA may involve the PD1/PDL1 pathway and increased caspase 3, leading to permanent hair loss.